A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

Sponsor

Mirati Therapeutics Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT00324194

Collaborator

(none)

Enrollment

Locations

Arm

Duration (Months)

6.3

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In this study, MGCD0103, a new anticancer drug under investigation, is given twice weekly to patients with leukemia or myelodysplastic syndromes.

Condition or Disease	Intervention/Treatment	Phase
Leukemia Myelodysplastic Syndromes	Drug: MGCD0103	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

25 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I Study of MGCD0103 Given as a Twice Weekly Oral Dose in Patients With Leukemia or Myelodysplastic Syndromes

Study Start Date :

Feb 1, 2005

Actual Primary Completion Date :

Mar 1, 2008

Actual Study Completion Date :

Aug 1, 2008

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1 MGCD0103 oral dose 2 times per week.	Drug: MGCD0103 MGCD0103 oral dose given 2 times per week.

Arm

Intervention/Treatment

Experimental: 1

MGCD0103 oral dose 2 times per week.

Drug: MGCD0103

MGCD0103 oral dose given 2 times per week.

Outcome Measures

Primary Outcome Measures

Safety and tolerability. [1 year (anticipated)]

Secondary Outcome Measures

Clinical response. [1 year (anticipated)]
Dose limiting toxicities [1 year (anticipated)]
Pharmacokinetics [1 year (anticipated)]
Pharmacodynamics (histone acetylation, biomarkers) [1 year (anticipated)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients must have a diagnosis of one of the following:
relapsed or refractory AML or ALL that has failed to respond to standard therapy, has progressed despite standard therapy.
relapsed or refractory Myelodysplastic Syndromes including CMML (chronic myelomonocytic leukemia) or other myeloproliferative disorders provided there is an MDS component.
previously untreated AML or Myelodysplastic Syndromes in patients >60 years of age who refused or are not candidates for induction chemotherapy
Patients with relapsed or refractory CML that has failed to respond to imatinib therapy or standard therapy, has progressed despite standard therapy, or for which no standard therapy exists.
ECOG performance status of 0, 1, or 2.
Age ≥18 years.
Laboratory requirements.
Patients or their legal representative must be able to read, understand, and sign a written informed consent (approved by the IRB/EC) prior to study entry.

Exclusion Criteria:

Patients with other active malignancy except basal cell carcinoma or cervical intraepithelial neoplasia (CIN / cervical in situ).
Patients with suspicion of CNS involvement (tests are not required to rule out CNS involvement in the absence of signs or symptoms).
Pregnant or lactating women. Women of child-bearing potential must have a negative serum pregnancy test documented within 7 days prior to registration on study.
Patients and their partners, if either are of childbearing potential, not using adequate birth control measures throughout the course of the study. Both men and women enrolled on study must agree to use a medically acceptable effective form of contraception during the study and for 90 days following the last dose of study medication. An effective form of contraception is an oral contraceptive or a double barrier method, such as condom with diaphragm.
Patients with serious illnesses, medical conditions, or other medical history, including laboratory results, which, in the investigator's opinion, would be likely to interfere with a patient's participation in the study, or with the interpretation of the results.
Patients who have been treated with any investigational drug within 30 days prior to study initiation (an investigational drug is one for which there is no approved indication), or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy.
Known hypersensitivity to any of the components of MGCD0103.
Known HIV or Hepatitis B or C (tests do not need to be performed to rule out any of these infections).
Any psychiatric illness/social situations that would, in the judgment of the investigator, limit compliance with study requirements.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Lee Moffitt Cancer Center	Tampa	Florida	United States	33612
2	University of Chicago Medical Center	Chicago	Illinois	United States	60637
3	Columbia University Medical Center	New York	New York	United States	10032
4	Sir Mortimer Davis Jewish General Hospital	Montreal	Quebec	Canada